Biofarm announced a net profit of 43.6 million RON in the first half of the year, increasing by 20 percent compared to the same period of 2021.

“In the first half of this year, we recorded solid financial results in a sensitive geopolitical context marked by inflationary pressures. We are confident that even this year, marked by the increase in the price of raw materials and the increase in production costs, we will achieve our main objective, which is to strengthen our position in the local pharmaceutical market and in foreign markets with the help of a competitive portfolio based on the real needs of the market,” said Catalin Vicol, general manager of Biofarm.

Biofarm recorded positive developments in the Consumer Healthcare (CHC) category, both in terms of volume and value. The therapeutic areas with the greatest contribution to the growth of the CHC category in the first six months were: Cold & Flu, Sore Throat and Pain Management. Biofarm brands covering these therapeutic areas recorded significant double-digit sales in line with the growth trend.

In the first 6 months of 2022, Biofarm ranked 3rd in the Consumer Healthcare (CHC) segment in terms of units sold.